Date | Insider | Price | Amount |
---|---|---|---|
3-26-2024 Insider Buy |
Ankur Dhingra Chief Financial Officer |
$3.75 CAGR » |
$375,000.00 100,000 shares |
3-27-2024 Insider Buy |
Mahkam Zanganeh Chief Executive Officer |
$3.73 CAGR » |
$411,094.12 110,321 shares |
12-12-2023 Insider Buy |
Mahkam Zanganeh Chief Executive Officer |
$2.07 CAGR » |
$10,350.00 5,000 shares |
12-13-2023 Insider Buy |
Ankur Dhingra Chief Financial Officer |
$2.17 CAGR » |
$44,254.00 20,400 shares |
10-13-2023 Insider Buy |
Manmeet Singh Soni Chief Operating Officer |
$1.68 CAGR » |
$4,999,999.20 2,976,190 shares |
3-8-2023 Insider Buy |
Mahkam Zanganeh Co-CEO & President |
$1.05 CAGR » |
$24,703,396.20 23,527,044 shares |
8-16-2022 Insider Buy |
Ankur Dhingra Chief Financial Officer |
$0.97 CAGR » |
$36,554.45 37,685 shares |
3-6-2023 Insider Buy |
Robert W. Duggan Chief Executive Officer |
$1.05 CAGR » |
$395,314,374.00 376,489,880 shares |
8-16-2022 Insider Buy |
Maky Zanganeh Co-CEO & President |
$0.97 CAGR » |
$5,634,858.04 5,809,132 shares |
8-16-2022 Insider Buy |
Robert W. Duggan Chief Executive Officer |
$0.97 CAGR » |
$92,003,726.91 94,849,203 shares |
8-16-2022 Insider Buy |
Ankur Dhingra Chief Financial Officer |
$0.97 CAGR » |
$35,128.55 36,215 shares |
5-12-2021 Insider Buy |
Robert W. Duggan Chief Executive Officer |
$5.24 CAGR » |
$59,557,426.04 11,365,921 shares |
5-12-2021 Insider Buy |
Maky Zanganeh Chief Operating Officer |
$5.24 CAGR » |
$2,038,763.48 389,077 shares |
11-6-2020 Insider Buy |
Robert W. Duggan Chief Executive Officer |
$3.34 CAGR » |
$46,999,999.04 14,071,856 shares |
Also See: Institutional Holders of SMMT
Also See: SEC filings
Growth of $10,000.00 Without Dividends Reinvested |
||
Start date: | 03/27/2024 | |
End date: | 05/02/2024 | |
Start price/share: | $3.75 | |
End price/share: | $4.06 | |
Dividends collected/share: | $0.00 | |
Total return: | 8.27% | |
Annualized Gain: | 83.81% | |
Starting investment: | $10,000.00 | |
Ending investment: | $10,827.00 | |
Years: | 0.10 |
Summit Therapeutics Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent Summit Therapeutics insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding SMMT
Free SMMT Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Other companies seeing insider buying close in time to when the Summit Therapeutics Insider Buying occurred are:
Daxor Insider Buying |